Research
Hormonal
GLP-1RAs reduce the risk of hospitalization for heart failure (HF) and prevent new-onset HF, although they may not reduce readmissions in patients with existing HF.
For patients with type 2 diabetes who are at risk for heart failure, GLP-1RAs can help prevent the initial development of heart failure and reduce the likelihood of being hospitalized for it. However, if you already have heart failure, these medications may not prevent future hospital readmissions, though they still offer other cardiovascular benefits.
WeakQualifiesHIGH confidence
In the same meta-analysis, the relative risk of hospital admission for HF was also reduced by 11% in patients treated with GLP-1RAs (HR 0.89 [95% CI 0.82, 0.98])... A recent meta-analysis corroborates this hypothesis, reporting that GLP-1RAs prevent hospitalisation for new-onset HF but do not reduce HF readmissions in patients with previous HF history.
Why this rating
Supported by meta-analysis of CVOTs and secondary analyses.
Source
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Anna Solini et al. · Diabetologia · 2023
DOI 10.1007/s00125-023-05973-w
narrative_reviewCited 29×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual and triple incretin receptor agonists (e.g., tirzepatide, retatrutide) show potential for greater cardiovascular risk factor reduction than single GLP-1RAs, though definitive cardiovascular outcome trial results are pending.Limited
- Long-acting GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes, particularly those with established cardiovascular disease or high cardiovascular risk.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →